UNSPSC 51412003: Butalamine hydrochloride

This classification denotes a vasodilating agent with the molecular formula C18H28N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 140T9JTG43, chemically known as 1,2-ethanediamine, n,n-dibutyl-n-(3-phenyl-1,2,4-oxadiazol-5-yl)- but generally known as butalamine, which bears US NIH Compound Identifier 30949. Butalamine most often comes in base and hydrochloride forms. European Medicines Agency schedules Butalamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05998MIG.

UNSPSC 51412003 Butalamine hydrochloride is a Commodity code covering individual pharmaceutical active ingredients and finished-dose medications procured by state and local health and safety agencies for emergency medical services, institutional healthcare, and pharmacy benefit programs. State and local governments buy this code as part of broader advanced life support medication supplies, hospital formularies, and pharmacy benefit management initiatives rather than butalamine in isolation. Issuing bodies include city fire and rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances administering pharmacy programs on behalf of member state and local jurisdictions. The Tampa Fire Rescue procurement shows typical scope: sealed competitive bidding for specific finished-dose medications with firm pricing, expiration-date warranties, rapid delivery requirements, and small local business enterprise set-asides. The Texas HHS Commission and Minnesota MMCAP initiatives represent larger-scale pharmacy procurement vehicles that aggregate demand across multiple jurisdictions and establish standing contracts with manufacturers and wholesalers to supply generic pharmaceuticals including butalamine and related active pharmaceutical ingredients to participating agencies and health plans.

Recent activity concentrates in Florida, Texas, and Minnesota. The City of Tampa issued an IFB (Bid No. 26P00188) on April 24, 2026, for advanced life support medications including labetalol HCI, epinephrine, adenosine, and diltiazem vials with a response deadline of April 8, 2026 and estimated contract value of $40,000, reserved with a 5 percent small local business enterprise bid discount. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities for a Direct-to-Manufacturer Prescriptions program as preliminary research before issuing a formal RFP. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued an RFP (S1070000015802) due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with awarded vendors effective July 1, 2026, and a two-year initial contract term. Price competitiveness weighted at 75 percent in the MMCAP RFP indicates aggressive cost competition in cooperative purchasing vehicles.